Compugen (NASDAQ:CGEN) Shares Cross Above 200-Day Moving Average – Time to Sell?

Compugen Ltd. (NASDAQ:CGEN) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.82 and traded as high as $2.25. Compugen shares last traded at $2.22, with a volume of 407,537 shares.

Wall Street Analyst Weigh In

Separately, Oppenheimer assumed coverage on shares of Compugen in a research report on Monday, January 13th. They issued an “outperform” rating and a $4.00 price target for the company.

Compugen Price Performance

The firm has a market capitalization of $198.11 million, a PE ratio of 111.00 and a beta of 2.65. The company has a 50-day moving average price of $1.95 and a 200 day moving average price of $1.82.

Institutional Investors Weigh In On Compugen

A number of institutional investors have recently added to or reduced their stakes in CGEN. Oppenheimer & Co. Inc. boosted its position in shares of Compugen by 75.9% during the third quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 8,350 shares during the last quarter. Commonwealth Equity Services LLC purchased a new stake in Compugen in the 4th quarter worth $32,000. Two Sigma Advisers LP boosted its holdings in shares of Compugen by 93.6% during the 4th quarter. Two Sigma Advisers LP now owns 35,784 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 17,300 shares during the last quarter. Joel Isaacson & Co. LLC grew its position in shares of Compugen by 136.4% during the third quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock valued at $94,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Compugen in the fourth quarter worth about $81,000. 12.22% of the stock is owned by hedge funds and other institutional investors.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.